Business Context and Reporting Period
Zentalis Pharmaceuticals, Inc. (ZNTL) filed a Current Report on Form 8-K dated April 17, 2026. The filing serves as a Regulation FD disclosure regarding the issuance of a press release and the presentation of scientific posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
Key Financial Metrics
This filing is a non-financial event report. The text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes
There are no material financial changes reported in this filing. The primary activity is the dissemination of scientific data and corporate announcements via the AACR Annual Meeting.
Guidance, Outlook, and Management Commentary
- Scientific Presentations: The Company presented two posters at the AACR Annual Meeting:
- WEE1 Inhibition as a Therapeutic Strategy in Triple-Negative Breast Cancer: Evaluating single agent and combination activity of Azenosertib in preclinical models.
- Real-World Treatment Patterns and Outcomes: Revealing distinct clinical trajectories of patients with Cyclin E1-Positive Ovarian Cancer.
- Legal Status of Information: The information contained in the press release and posters (Exhibits 99.1, 99.2, and 99.3) is deemed "furnished" and not "filed" for purposes of Section 18 of the Exchange Act. Consequently, this information is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific details on the scientific findings and any forward-looking statements regarding clinical timelines.
- Examine Exhibits 99.2 and 99.3 to understand the preclinical data for Azenosertib and real-world evidence for Cyclin E1-Positive Ovarian Cancer.
- Verify the Company's latest financial position in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor subsequent filings for any updates on the clinical development of Azenosertib based on the AACR presentation.